SCHEMBL15655811

SCHEMBL15655811

CC(=O)Nc1[nH]nc(-c2cccc(F)c2)c1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.47
▸ ADORA2A P29274 1/20 0.47
▸ ADORA2B P29275 1/20 0.47
▸ ADORA1 P30542 1/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ GSK3A P49840 3/20 0.45
▸ GSK3B P49841 3/20 0.45
▸ TOP2A P11388 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ MAP2K4 P45985 1/20 0.41
▸ MAPT P10636 4/20 0.40
▸ TTK P33981 3/20 0.40
▸ ALOX15 P16050 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ NFKB1 P19838 2/20 0.40
▸ NFKB2 Q00653 2/20 0.40
▸ RELA Q04206 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19806682 0.84 RAB9A (0.58) ADORA3ADORA2ARAB9AGSK3BMAP2K4
SCHEMBL18301578 0.84 GSK3A (0.51) ADORA3ADORA1RAB9AGSK3AGSK3B
SCHEMBL19441266 0.80 MAPT (0.40) ADORA2BADORA1RAB9AGSK3AGSK3B
SCHEMBL15655494 0.78 GSK3A (0.45) ADORA3ADORA2AADORA2BADORA1RAB9A
SCHEMBL2863255 0.74 TTK (0.47) ADORA3ADORA2AADORA2BADORA1GSK3A
SCHEMBL2868379 0.74 TTK (0.47) ADORA3ADORA2AADORA2BADORA1GSK3A
SCHEMBL4149829 0.73 ADORA3 (0.57) ADORA3ADORA2AADORA2BADORA1RAB9A
SCHEMBL5271443 0.73 CHEK1 (0.57) RAB9AMAPTTTKSMN1; SMN2MEN1
SCHEMBL15656702 0.72 MAPT (0.48) ADORA3ADORA2AADORA2BADORA1RAB9A
SCHEMBL2860783 0.72 MAP2K4 (0.52) ADORA3ADORA2AADORA2BADORA1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2911671-B1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE INC (US) 2018-06-27 — — EP disclosed
EP-2911671-B1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE INC (US) 2018-06-27 — — EP disclosed
US-9783545-B2 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome USHER III INITIATIVE, INC. (US) 2017-10-10 — — US disclosed
US-9783545-B2 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome USHER III INITIATIVE, INC. (US) 2017-10-10 — — US disclosed
US-9783545-B2 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome USHER III INITIATIVE, INC. (US) 2017-10-10 — — US disclosed
US-20160272647-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME BIOFOCUS DPI LTD. (GB) 2016-09-22 — — US disclosed
US-20160272647-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME BIOFOCUS DPI LTD. (GB) 2016-09-22 — — US disclosed
US-20160272647-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME BIOFOCUS DPI LTD. (GB) 2016-09-22 — — US disclosed
US-9371332-B2 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome USHER III INITIATIVE, INC. (US) 2016-06-21 — — US disclosed
US-9371332-B2 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome USHER III INITIATIVE, INC. (US) 2016-06-21 — — US disclosed
US-20140121205-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE (US) 2014-05-01 — — US disclosed
US-20140121205-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE (US) 2014-05-01 — — US disclosed
US-20140121205-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE (US) 2014-05-01 — — US disclosed
US-20140121197-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. 2014-05-01 — — US disclosed
US-20140121197-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. 2014-05-01 — — US disclosed
US-20140121197-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. 2014-05-01 — — US disclosed
WO-2014066835-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. (US) 2014-05-01 — — WO disclosed
WO-2014066836-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. (US) 2014-05-01 — — WO disclosed
WO-2014066836-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. (US) 2014-05-01 — — WO disclosed
WO-2014066835-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME USHER III INITIATIVE, INC. (US) 2014-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272647-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME ALDH1A2, ALDH1A3, NR2E3 ADORA3 692/4885ADORA2A 375/4885ADORA2B 1639/4885
US-20140121205-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME ALDH1A2, ALDH1A3, PSEN2 ADORA3 980/4885ADORA2A 598/4885ADORA2B 1708/4885
US-20140121197-A1 PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME ALDH1A2, ALDH1A3, NR2E3 ADORA3 692/4885ADORA2A 375/4885ADORA2B 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback